Seattle Genetics strike another alliance deal with Bayer
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADCETRIS, ADCs, alliance, Antibody-drug conjugates, ASCO, Bayer, FDA, Immunogen, innovator, Kadcyla, Lymphoma, oncology, pharmaceutical, Roche, seattle genetics, Takeda
Leave a comment
Polyphor begin Board succession with appointment of pharmaceutical Senior Executives
Authored by Karl Simpson
Posted in Pharmaceutical business, Recruitment Market
Tagged Alpha Antitryspin Deficiency, bioValley, board appointment, board executives, Chairman, CXCR4 antagonist, Cystic Fibrosis, Jean-Jacques Garaud, Jerry Karabelas, neutrophil elastase, Novartis, oncology, Pharmacueticals, POL6326, POL7080, Polyphor, Research & Early development, Roche, Switzerland, Worldwide Pharmaceutical
Leave a comment
Inflection Biosciences closes initial funding round and licenses new compounds
Authored by James Sheppard
Biotech IPO fever spreads from West to East
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Ataluren, Biopolis, cardiomyocytes, derived neurons, DMD, Duchenne Muscular Dystrophy, Human iPSC, Institute of Medical Sciences, IPO, Japan, JASDAQ, Kyoto University, Malaysia Biotech, New Zealand Biotech, Prof. Hiromitsu Nakauchi, Prof. Norio Nakatsuji, PTC Therapeutics, ReproCELL, Stem Cell, University of Tokyo
Leave a comment
Kurma Life Science Partners Launches new Biotech Fund for Rare Diseases
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Avalon Ventures, BLiNK, CDC Enterprise, DMD, Duchenne Muscular Dystrophy, European Research Institutes, France, GSK, Idinvest Partners, KLS Partners, Kurma, Kurma Biofund, Kurma Life Science Partners, NEA, New Enterprise Associates, oncology, Orphan drugs, partnering, Prosensa, rare diseases, VC, venture capital
Leave a comment
Bluebird IPO shows gene therapy on upward trajectory
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Agios Pharmaceuticals, Bluebird bio, Cardio3 Bioscience, celgene, childhood cerebral ALD, Epizyme, europe, Gene therapy, haematology, IPO, IPO Window, Lenti D, Nick Leschly, oncology, Onconova Therapeutics, Prosensa, public offering, shares, Shire, Shire HGT, Third Rock Ventures, USA
Leave a comment
Johnson & Johnson grows prostate cancer franchise with Aragon purchase
Authored by James Sheppard
